TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$5.63 USD
-0.01 (-0.18%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $5.66 +0.03 (0.53%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for TScan Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 192 | 120 | 161 | 35 | 42 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 4 | 4 | 2 | 1 |
Total Current Assets | 194 | 124 | 166 | 36 | 42 |
Net Property & Equipment | 8 | 10 | 12 | 6 | 2 |
Investments & Advances | 2 | 1 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 5 | 1 | 1 |
Total Assets | 272 | 199 | 188 | 50 | 49 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 2 | 3 | 1 |
Current Portion Long-Term Debt | 3 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 7 | 7 | 2 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 4 | 11 | 11 | 0 |
Total Current Liabilities | 30 | 17 | 21 | 17 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 0 | 2 | 9 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 27 | 29 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 60 | 60 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 121 | 100 | 27 | 92 | 67 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 398 | 258 | 253 | 1 | 0 |
Retained Earnings | -248 | -158 | -92 | -44 | -17 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 151 | 99 | 161 | -42 | -17 |
Total Liabilities & Shareholder's Equity | 272 | 199 | 188 | 50 | 49 |
Total Common Equity | 151 | 99 | 161 | -42 | -17 |
Shares Outstanding | 47.80 | 24.20 | 23.70 | NA | NA |
Book Value Per Share | 3.16 | 4.11 | 6.78 | 0.00 | 0.00 |
Fiscal Year End for TScan Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 298 | 163 | 192 | 215 | 209 |
Receivables | 0 | 0 | 0 | 0 | 32 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 2 | 1 |
Total Current Assets | 300 | 165 | 194 | 218 | 242 |
Net Property & Equipment | 8 | 7 | 8 | 9 | 8 |
Investments & Advances | 2 | 2 | 2 | 2 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 5 | 5 | 5 |
Total Assets | 375 | 241 | 272 | 291 | 317 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 2 | 3 | 3 |
Current Portion Long-Term Debt | 10 | 7 | 3 | 1 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 9 | 11 | 9 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11 | 10 | 10 | 15 | 19 |
Total Current Liabilities | 39 | 31 | 30 | 33 | 35 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 5 | 6 | 8 | 8 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 20 | 23 | 27 | 29 | 30 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 120 | 118 | 121 | 122 | 126 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 565 | 401 | 398 | 397 | 396 |
Retained Earnings | -309 | -278 | -248 | -228 | -205 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 255 | 123 | 151 | 169 | 191 |
Total Liabilities & Shareholder's Equity | 375 | 241 | 272 | 291 | 317 |
Total Common Equity | 255 | 123 | 151 | 169 | 191 |
Shares Outstanding | 52.90 | 47.90 | 47.80 | 47.80 | 47.80 |
Book Value Per Share | 4.82 | 2.57 | 3.16 | 3.53 | 3.99 |